GlassScriptPhysician profile
Smitha Unnikrishnan
NPI 1750889549
$2,905.03
in general payments reported to CMS, 2019-2025
23 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $818 · 2023: $1,026 · 2024: $802 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $511.79 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $304.53 | 2022-2024 | |
| Boston Scientific Corporation | $252.21 | 2022-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $241.26 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $224.71 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $224.25 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.28 | 2022-2025 | Jardiance |
| Abbott Laboratories | $174.29 | 2021-2023 | Mitraclip |
| Cvrx, INC. | $159.44 | 2022-2025 | Barostim Neo System |
| Medtronic, INC. | $112.57 | 2021-2023 | Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.37 | 2023-2024 | Lifevest |
| Amgen INC. | $87.65 | 2022-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $54.61 | 2022-2023 | |
| Esperion Therapeutics, INC. | $43.15 | 2023-2024 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $37.71 | 2022-2023 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $28.72 | 2024 | Assure Wcd |
| Genzyme Corporation | $24.65 | 2022 | |
| Azurity Pharmaceuticals, INC. | $23.79 | 2023 | Edarbi |
| Cardiva Medical, INC. | $22.99 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Novo Nordisk INC | $22.68 | 2023 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $19.19 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $18.72 | 2021 | |
| Bioventus LLC | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Unnikrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.